Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Rhythm Pharmaceuticals (RYTM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PTC Therapeutics (PTCT – Research Report) and ...
7RYTM : Analyst Expectations For Rhythm Pharmaceuticals&#...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...
Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?
We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $66.00 at Needham & Company LLC
Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...
ETF Daily News6d
Rhythm Pharmaceuticals’ (RYTM) Buy Rating Reaffirmed at HC Wainwright
Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus ...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...
Explore more
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...
Morningstar13d
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...
The Bakersfield Californian12d
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with ...
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...